Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvastatin + Ezetimibe vs Fluvastatin in Primary Hypercholesterolemia
NCT00171288Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2003
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ezetimibe in hypercholesterolemia (2 arms), sponsored by Novartis. Primary endpoint: Low Density Lipoprotein Cholesterol at 12 weeks. Started Aug 2003; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00171288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171288.